To ensure a COVID-19 vaccine test this November, Joko Widodo' ministers meet manufacturers in China and Europe. Last week, coordinating minister for maritime and investment affairs, Luhut Binsar Pandjaitan, together with minister of health, Terawan Agus Putranto, and CEO of drug-maker, PT Bio Farma, Honesti Basyir, has met Cansino, Sinopharm, and Sinovac - Photo by CMMA Office

JAKARTA (TheInsiderStories) – To ensure a COVID-19 vaccine test this November, Joko Widodo’ ministers meet manufacturers in China and Europe. Last week, coordinating minister for maritime and investment affairs, Luhut Binsar Pandjaitan, together with minister of health, Terawan Agus Putranto, and CEO of drug-maker, PT Bio Farma, Honesti Basyir, has met Cansino, Sinopharm, and Sinovac.

While, foreign minister, Retno Marsudi, and state own minister, Erick Thohir, will travel to England and Switzerland on the same discussions. The ministers will also hold a meetings and discussions with the Director General of World Health Organization, Global Alliance for Vaccines and Immunization, Coalition for Epidemic Preparedness Innovations within the framework of the COVAC facility.

At the official statement released on Sunday (10/12), Putranto said the government will carry out simulations in several health centers. Since the end of September, training has also been carried out for health workers on the procedures for the vaccination.

As known, vaccines from the three companies have entered the final stage of clinical trial phase 3 and are in the process of obtaining Emergency Use Authorization in a number of countries. Cansino is conducting phase 3 clinical trials in China, Saudi Arabia, Russia and Pakistan.

Then, Sinopharm conducted Phase 3 clinical trials in China, United Arab Emirates (UAE), Peru, Morocco and Argentina. While, Sinovac is conducting clinical trials in phase 3 in China, Indonesia, Brazil, Turkey, Bangladesh, and Chile.

The three companies obtained Emergency Use Authorization from the Chinese Government in July 2020. The UAE Government also provided emergency use authorization to G42 produced by SinopharmThe number of vaccines covered by each company varies, depending on production capacity and commitments to other buyers.

For this year, Cansino has undertaken 100,000 vaccines (single dose) in November 2020 and around 20 million for 2021. Sinopharm undertakes 15 million doses of vaccine (dual dose) in this year, of which 5 million doses will begin coming next month.

While, Sinovac has committed 3 million doses of vaccine by the end of December, with a commitment to deliver 1.5 million doses of vaccine (single dose vials) in the first week of November, another 1.5 million doses of vaccine (single dose vials) in the first week of December 2020, plus 15 million doses of vaccine in bulk form. For 2021, Sinopharm seeks 50 million (dual dose), Cansino 20 million (single dose), Sinovac 125 million (dual dose).

“China is willing to cooperate with Indonesia in vaccine research, production and distribution, as well as support exchanges between related medical research institutions to help ensure access to affordable vaccines throughout the region and around the world,” said Chinese foreign minister, Wang Yi, after the meeting.

While, today, Marsudi said in a virtual presser, she and Thohir will also have a diplomatic meetings with the British foreign minister, Swiss’ Vice President, and meet several companies from Switzerland.

Written by Editorial Staff, Email: theinsiderstories@gmail.com